M. Kirby

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

F. Fossella, P. Lorigan, P. Woll, 2016, Investigational New Drugs.

Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.

Jenny C. Chang, V. Semiglazov, T. Spector, 2014, Clinical breast cancer.

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.

S. Jagannath, A. Chanan-Khan, S. Ailawadhi, 2019, Clinical lymphoma, myeloma & leukemia.

A phase I, first-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors.

M. Birrer, P. LoRusso, K. Sankhala, 2013 .

Phase 1 study of IMGN853, a folate receptor alpha (FR{alpha})-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.

A. Oza, M. Birrer, H. Borghaei, 2015 .

Preliminary single agent activity of IMGN853, a folate receptor alpha (FR{alpha})-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.

A. Oza, M. Birrer, R. Perez, 2015 .

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.

S. Jagannath, A. Chanan-Khan, S. Ailawadhi, 2019, Clinical lymphoma, myeloma & leukemia.

IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single-agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).

M. Birrer, U. Matulonis, R. Perez, 2016 .